In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...